MAPT and Alzheimer disease: We compared the performances of two commonly used platforms, an enzyme-linked immunosorbent assay (ELISA) and a multiplex (xMAP) technology for measurement of CSF Aβ1–42, total tau (T-tau), and phosphorylated tau 181 (P-tau181p) proteins, in 30 AD patients and 28 control subjects.